神経治療学
Online ISSN : 2189-7824
Print ISSN : 0916-8443
ISSN-L : 2189-7824
Editorial(論説)
神経治療学のこれから:医師主導治験で考えたこと
桑原 聡
著者情報
ジャーナル フリー

2017 年 33 巻 4 号 p. 499-501

詳細
抄録

The Japanese POEMS syndrome with Thalidomide (J–POST) Trial is a phase II/III multicenter, double–blinded, randomized, controlled trial that aims to evaluate the efficacy and safety of a treatment with thalidomide in POEMS (crow–Fukase) syndrome. In this editorial, thoughts, opinions, and efforts to perform this investigator–lead clinical trial are described. A clinical trials are tough work, requiring a large amount of time, effort, and money, but it also give a great achievement for patients with intractable disease, and doctors and medical staffs involved in the trial. The advantage for the investigators includes expanding motivation for better and update understanding of the disease, as well as growing as a physician. The idea for novel treatments is more likely to be arising from young neurologists. Definitely this approach is necessary for rare diseases. The Japanese Society of Neurological Therapeutics should play an important role in the spread of clinical trial with novel treatments.

著者関連情報
© 2017 日本神経治療学会
前の記事 次の記事
feedback
Top